Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2025 results , with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was ...

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, ...

Omnicell, Inc., a small-cap medical technology solutions provider, posted its Q1 results Tuesday. Both the top and bottom-line results beat the consensus. However, thanks to some new headlines and ...

Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% ...

In the preceding three months, 7 analysts have released ratings for Omnicell (NASDAQ:OMCL), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view of ...

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the ...